FIELD: trilithium salt of phospho-ascorbic acid use.
SUBSTANCE: invention relates to the use of a trilithium salt of phospho-ascorbic acid with the formula Li3C6H6O9P as a radiosensitizing agent, which can be used in the treatment of cancer with radiation therapy to increase the radiosensitivity of malignant cells.
EFFECT: expanding the arsenal of drugs with radiosensitizing activity.
1 cl, 2 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR OBTAINING THE TRILITHIUM SALT OF PHOSPHO-ASCORBIC ACID | 2020 |
|
RU2752829C1 |
RADIOSENSITIZING AGENT | 2024 |
|
RU2833916C1 |
TUMOUR CELL RADIOSENSITIZATION METHOD | 2024 |
|
RU2834199C1 |
RADIOSENSITIZER | 2019 |
|
RU2720455C1 |
CARDIOPROTECTIVE AND ANTIARRHYTHMIC MEDICINE | 2022 |
|
RU2783444C1 |
PHOTOSENSITIZER FOR PHOTODYNAMIC DESTRUCTION OF TUMOR CELLS | 2023 |
|
RU2805148C1 |
SOMASTATINIC PEPTIDES, RADIOPHARMACEUTICAL AGENT, METHOD OF TREATING TUMORS, AND PHARMACEUTICAL COMPOSITION | 1995 |
|
RU2156774C2 |
RADIOPROTECTIVE, RADIOMITIGATORY AND RADIOSENSITIZING AGENT BASED ON SODIUM SALT OF AMINODIHYDROPHTHALAZINEDIONE SODIUM (DRUG TAMERON) AND OTHER ALKALI AND ALKALINE EARTH METAL SALTS OF AMINODIHYDROPHTHALAZINEDIONE | 2022 |
|
RU2804886C1 |
RADIOPROTECTIVE AGENT | 2020 |
|
RU2737898C1 |
SENSITIZER FOR PHOTODYNAMIC DESTRUCTION OF TUMOR CELLS | 2021 |
|
RU2771237C1 |
Authors
Dates
2022-01-11—Published
2021-04-28—Filed